Human papillomavirus status in advanced cervical cancer: Predictive and prognostic significance for curative radiation treatment

International Journal of Gynecological Cancer

Volumn 15, Issue 2, 2005, Pages 278-284

  Lindel, K ^a,c   Burri, P ^a   Studer, H U ^a   Altermatt, H J ^b   Greiner, R H ^a   Gruber, G ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Pathology Laenggasse   (Switzerland)

^c Radiologische Klinik   (Germany)

Author keywords

Cervical cancer; Human papillomavirus; Radiation

Indexed keywords

DNA; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FISHER EXACT TEST; HOST CELL; HUMAN; HUMAN TISSUE; METRITIS; NONHUMAN; PARAMETER; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIATION RESPONSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; UTERINE CERVIX CANCER; VIRUS GENE; VIRUS INFECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; DNA, VIRAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 15444364080     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.15216.x     Document Type: Article

References (29)

1. Spandidos DA, Dokianakis DN, Kallergi G, Aggelakis E. Molecular basis of gynecological cancer. Ann N Y Acad Sci 2000;900:56-64.
2. Scheffner M, Romanczuk H, Munger K, Huibregtse JM, Mietz JA, Howley PM. Functions of human papillomavirus proteins. Curr Top Microbiol Immunol 1994;186:83-99.
3. Thomas M, Pim D, Banks L. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 1999;18:7690-700.
4. Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B, Johansson B, Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 1998;17:146-53.
5. Vernon SD, Unger ER, Miller DL, Lee DR, Reeves WC. Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int J Cancer 1997;74:50-6.
6. Desaintes C, Goyat S, Garbay S, Yaniv M, Thierry F. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. Oncogene 1999;18:4538-45.
7. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-13.
8. Lavergne D, de Villiers EM. Papillomavirus in esophageal papillomas and carcinomas. Int J Cancer 1999;80:681-4.
9. Greer CE, Peterson SL, Kiviat NB, Manos MM. PCR amplification from paraffin-embedded tissues. Effects of fixative and fixation time. Am J Clin Pathol 1991;95:117-24.
10. Kleter B, van Doorn LJ, ter Schegget J et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses [see comments]. Am J Pathol 1998;153:1731-9.
11. de Roda Husman AM, Walboomers JM, van den Brule AJ, Meijer CJ, Snijders PJ. The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papilloma-virus detection by PCR. J Gen Virol 1995;76(Pt 4):1057-62.
12. Karlsen F, Kalantari M, Jenkins A et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996;34:2095-100.
13. zur Hausen H Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000;92:690-8.
14. Riou G, Favre M, Jeannel D, Bourhis J, Le Doussal V, Orth G. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990;335:1171-4.
15. Pilch H, Gunzel S, Schaffer U et al. The presence of HPV DNA in cervical cancer: correlation with clinicopathologic parameters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 2001;11:39-48.
16. Hampson L, El Hady ES, Moore JV, Kitchener H, Hampson IN. The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J 2001;15:1445-7.
17. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci USA 1998;95:2290-5.
18. Butz K, Whitaker N, Denk C, Ullmann A, Geisen C, Hoppe-Seyler F. Induction of the p53-target gene GADD45 in HPV-positive cancer cells. Oncogene 1999;18:2381-6.
19. Huang RP, Fan Y, Peng A et al. Suppression of human fibrosarcoma cell growth by transcription factor, Egr-1, involves down-regulation of Bcl-2. Int J Cancer 1998;77:880-6.
20. Ishikawa H, Mitsuhashi N, Sakurai H, Maebayashi K, Niibe H. The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with stage IIIB cervical carcinoma treated with radiation therapy alone. Cancer 2001;91:80-9.
21. Harima Y, Sawada S, Nagata K, Sougawa M, Ohnishi T. Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. Int J Cancer 2001;96:286-96.
22. Haraf DJ, Nodzenski E, Brachman D et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996;2:755-62.
23. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers [see comments]. J Natl Cancer Inst 2000;92:709-20.
24. Chen CA, Chen TM, Wu CC, Chang CF, Hsieh CY. Human papillomavirus DNA and p53 status in stage IB bulky cervical cancer. J Cancer Res Clin Oncol 1994;120:678-82.
25. Nishimura A, Ono T, Ishimoto A et al. Mechanisms of human papillomavirus E2-mediated repression of viral oncogene expression and cervical cancer cell growth inhibition. J Virol 2000;74:3752-60.
26. Massimi P, Pim D, Bertoli C, Bouvard V, Banks L. Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 1999;18:7748-54.
27. Wells SI, Francis DA, Karpova AY, Dowhanick JJ, Benson JD, Howley PM. Papillomavirus E2 induces senescence in HPV-positive cells via pRB- and p21 (CIP)-dependent pathways. EMBO J 2000;19:5762-71.
28. Webster K, Parish J, Pandya M, Stern PL, Clarke AR, Gaston K. The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 2000;275:87-94.
29. Sanchez-Perez AM, Soriano S, Clarke AR, Gaston K. Disruption of the human papillomavirus type 16 E2 gene protects cervical carcinoma cells from E2F-induced apoptosis. J Gen Virol 1997;78(Pt 11):3009-18.